Sign up to save your podcasts
Or
Share NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
View all episodes
By NEJM Group
4.4
120120 ratings
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
138 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
501 Listeners
JACC This Week
172 Listeners
Clinical Conversations
58 Listeners
Mayo Clinic Talks
289 Listeners
BMJ Best Practice Podcast
26 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
136 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Curbside Consults
90 Listeners
Leadership Conversations
5 Listeners
Annals On Call Podcast
188 Listeners
JAMA Medical News
88 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Cardionerds: A Cardiology Podcast
432 Listeners
The Curious Clinicians
372 Listeners
NEJM AI Grand Rounds
58 Listeners
Intention to Treat
32 Listeners
Not Otherwise Specified
48 Listeners